

B2020056

**510(k) Summary of Safety and Effectiveness**

*Submitter Name and Address:* Baxter Healthcare Corporation  
Fenwal Division  
Route 120 and Wilson Road  
Round Lake, IL 60073

*Contact Person:* Steven B. Binion, Ph.D.  
Vice President, Regulatory Affairs  
Phone: (847)-270-4294  
Fax: (847)-270-2886

*Date of Summary:* November 13, 2002

*Trade/Proprietary Name of Device:* ALYX System

*Common/Usual Name of Device:* Automated Centrifugal Blood Cell Separator

*Classification Name of Device:* Automated Blood Cell Separator  
(21 CFR 864.9245)

*Legally Marketed Device Under Which Substantial Equivalence is Being Claimed:* Haemonetics MCS+ (BK960095)  
COBE Trima (BK990025)

*Device Description:* The ALYX apheresis instrument and disposable apheresis kit constitute a system for centrifugal blood separation. It is intended for use in blood collection establishments for the concurrent collection of two units of Red Blood Cells (2RBC). The instrument has pumps, clamps and valves that move donor blood through the disposable kit. The Red Blood Cells are collected with ACD-A anticoagulant and the remaining components are returned to the donor with 0.9% Sodium Chloride, USP. After addition of Red Cell Preservation solution the Red Blood Cells may be stored for 42 days. Leukoreduction of the collected Red Cell product occurs immediately post-collection by the leukoreduction filter.

*Intended Use of the Device:* The ALYX apheresis system is intended for use in blood collection establishments to collect and separate whole blood into its components.

B2070056

***Comparison of  
Technological  
Characteristics of the  
Device vs. the Legally  
Marketed Device:***


The function of the ALYX apheresis system is similar to that of other legally marketed devices such as the Haemonetics MCS+, the COBE Trima and other commercially available centrifugal-based blood cell separators. The ALYX system utilizes a closed system apheresis kit that incorporates processing solutions, tubing, a donor needle, a centrifuge chamber and blood product containers made from PVC.

***Brief Discussion of  
Nonclinical and Clinical  
Tests and Their Results  
Submitted in the  
Application:***

An initial clinical study was performed to evaluate the ALYX system for the concurrent collection of two units of Red Blood Cells. The study consisted of collection of two units of Red Blood Cells from 121 donors – 10 donors were female, 111 donors were male. 91 units were leukoreduced and stored for 42 days. 30 units were not leukoreduced and were stored for 42 days. In Vivo recovery studies were performed on 37 units. Studies were not performed to support gamma irradiation or freezing of Red Cells collected by the ALYX system. Additional studies performed on female donors of two units of Red Blood Cells within the weight range of 150 – 174 pounds demonstrated subject safety with minimal effects.

***Conclusion Drawn from the  
Nonclinical and Clinical  
Tests that Demonstrate that  
the Device is Safe,  
Effective, and Performs As  
Well As or Better Than the  
Legally Marketed Device:***

The results of the initial clinical study combined with those of this current study demonstrate that subject safety is maintained during the 2RBC procedures on the ALYX system. No adverse reactions beyond those that may typically be experienced in an automated apheresis procedure occurred during the initial and additional procedures. None of the adverse events reported were considered related to the device. All additional female subjects participating in a seven (7) day follow-up questionnaire stated that there was minimal disruption of their normal activities. The data demonstrate that collection of two units of Red Blood Cells with the ALYX system is safe for qualifying donors.

*for*   
\_\_\_\_\_  
Steven B. Binion  
Vice President, Regulatory Affairs  
Fenwal Division